INS and Hypoglycemia: According to meta-analyses, AID has shown to improve time in range (TIR, 70–180 mg/dL) an average of 9%–12% compared to other intensive insulin regimens, without an increase in hypoglycemia.1,2 Currently, the commercially available systems in the United States include the Tandem t:slim X2 with Control-IQ technology (CIQ), Minimed 670G/770G and 780G, Insulet Omnipod 5, and the iLet Bionic Pancreas.